Prenatal Diagnosis of Beta-Thalassemia
Beta-thalassemia is diagnosed during prenatal screening through a sequential approach: first identify at-risk couples via maternal screening (hemoglobin electrophoresis/HPLC showing elevated HbA2 >3.5%), then test the partner, and if both are carriers, proceed with invasive prenatal diagnosis using chorionic villus sampling (CVS) at 10-12 weeks or amniocentesis at 15-18 weeks, followed by DNA mutation analysis.
Screening Algorithm
Step 1: Identify Maternal Carrier Status
- Screen all pregnant women with complete blood count looking for microcytic hypochromic anemia (MCV <80 fL, MCH <27 pg)
- Apply discriminant indices to differentiate from iron deficiency:
- Mentzer index (MCV/RBC): <13 suggests thalassemia trait
- RDW index and MCH show excellent diagnostic performance 1
- Confirm with serum ferritin: >15 ng/mL in 95% of beta-thalassemia cases vs <15 ng/mL in iron deficiency 1
- Perform hemoglobin electrophoresis or HPLC: HbA2 >3.5% confirms beta-thalassemia trait 2, 3
Step 2: Partner Testing
Once maternal carrier status is confirmed, mandatory partner testing is required to determine fetal risk 4. The couple is at-risk only if both partners carry beta-thalassemia mutations or hemoglobin variants (25% risk of affected fetus per pregnancy).
Step 3: Prenatal Diagnosis for At-Risk Couples
Invasive procedures remain the gold standard 5, 6, 7, 8:
Timing and Method:
- First trimester (preferred): Chorionic villus sampling at 10-12 weeks gestation 5, 8
- Second trimester: Amniocentesis at 15-18 weeks or cordocentesis 5, 6
Laboratory Analysis:
- DNA mutation analysis via:
- Common mutations in various populations include IVS-I-110 (G>A), IVS-II-1 (G>A), IVS-I-6 (T>C), CD 41/42-TCTT 5, 7
Expected Results Distribution:
Emerging Non-Invasive Options
Non-invasive prenatal testing (NIPT) using digital PCR on maternal cell-free DNA is becoming available but not yet routine 10, 9:
- Analyzes cell-free fetal DNA from maternal plasma
- First screens for paternally inherited mutation (PIB)
- If PIB-positive, analyzes for maternally inherited mutation (MIB) using mutant/normal allele ratio
- Cut-off ≥0.919 for MIB detection: 100% sensitivity, 81.2% specificity 9
- For couples with identical mutations, cut-off ≥1.043: 100% sensitivity and specificity 9
- Currently limited by cost, availability, and need for validation in routine practice 10, 9
Critical Counseling Components
Genetic counseling must be provided before and after testing 4, 2, 3:
Essential Information to Convey:
- Nature of carrier state vs disease
- 25% recurrence risk with each pregnancy when both partners are carriers
- Clinical manifestations of transfusion-dependent thalassemia
- Available prenatal diagnostic options and timing
- Pregnancy termination as an option if fetus is affected
- Alternative: Preimplantation genetic diagnosis (PGD) for future pregnancies 6, 2
Counseling Effectiveness Factors:
Studies show better knowledge retention with 4:
- Younger maternal age
- Higher education level
- Prior awareness of carrier status
- Knowledge that partner is also a carrier
- No prior children
Videotape presentations are as effective as in-person counseling for conveying factual information and save professional time 4.
Important Caveats
- Cytogenetic analysis should be performed on excess fetal material from CVS/amniocentesis, as 2.3% of cases reveal chromosomal abnormalities 5
- Partner testing is required for each different partner in subsequent pregnancies—this point requires emphasis as patients often forget 4
- In regions with high prevalence, universal antenatal screening is recommended rather than selective screening 2, 3
- Severe anemia in beta-thalassemia trait carriers during pregnancy (hemoglobin <8 g/dL in 33%) increases risk of preeclampsia, postpartum hemorrhage, preterm birth, and IUGR 1